← boardnext 2026-08-31next 2026-11-23next 2027-05-31next 2027-11next 2028-02-29next 2029-01-03next 2030-05-31
EXEL
Exelixisdistress 0/10 · well-funded / low risk$54.800%today-4% from 52w high
Oncology 3
Lead: Renal Cell Carcinoma (RCC) · target PD-1
Revenue
$611M
Liquidity
$1426M
Runway
—
Shares 1y
-6%
Price & events
+23.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-1.6%
1W
+6.7%
1M
+19.0%
3M
+23.8%
6M
+20.7%
1Y
+144.0%
2Y
+227.6%
5Y
+166.9%
All
Overview
- Market Cap
- $13.77B
- Volume
- 119.87K
- 52 Week Range
- $34.54 – $57.10
- Total Shares
- 251.36M
- Float Shares
- 204.45M
- Short %
- 15.44%
- % Held by Insiders
- 1.82%
- % Held by Institutions
- 106.91%
- RVOL
- 0.05x
- Beta
- 0.42
Pipeline stages · 9 programs
XL092, Atezolizumab, Avelumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XB010, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XB628, Zanzalintinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XB371
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zanzalintinib, Nivolumab, Ipilimumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XL309, Olaparib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Cabozantinib, Zanzalintinib, Atezolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XL495, ADC cytotoxic agents
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
XB002, Nivolumab, BevacizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 13 trials · 10 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-31 Estimated 50% readout ~2026-09-30 final ~2027-02-28 | Phase 1 | XL092, Atezolizumab, Avelumab | Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer | — | active not recruiting |
| 2026-11-23 Estimated 50% readout ~2026-12-23 | Phase 1 | XB010, Pembrolizumab | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC) | — | recruiting |
| 2027-05-31 Estimated 50% readout ~2027-06-30 | Phase 1 | XB628, Zanzalintinib | Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor | — | recruiting |
| 2027-11 Estimated 50% readout ~2027-12-01 | Phase 1 | XB371 | Solid Tumors | — | recruiting |
| 2028-02-29 Estimated 50% readout ~2028-04-14 | Phase 2 | Zanzalintinib | Meningioma | — | recruiting |
Show all 13 trials · 8 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-08 Estimated 50% readout ~2028-10-15 | Phase 2/3 | Zanzalintinib, Pembrolizumab | Head and Neck Squamous Cell Carcinoma | — | active not recruiting |
| 2029-01-03 Estimated 50% readout ~2029-02-02 | Phase 1 | XL309, Olaparib | Advanced Solid Tumor | — | recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 2/3 | Zanzalintinib, Everolimus | Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | — | recruiting |
| 2030-05-31 Estimated 50% readout ~2030-08-14 | Phase 3 | Cabozantinib, Zanzalintinib, Atezolizumab | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer | — | not yet recruiting |
| 2030-06-28 Estimated 50% readout ~2030-07-28 | Phase 1 | Zanzalintinib, Nivolumab, Ipilimumab | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC) | — | recruiting |
| 2025-05-12 | Phase 1 | zanzalintinib, AB521, Nivolumab | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | 25 | terminated |
| 2025-05-07 | Phase 1 | XL495, ADC cytotoxic agents | Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis | 9 | terminated |
| 2025-03-10 | Phase 1 | XB002, Nivolumab, Bevacizumab | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 269 | completed |
Catalyst news & presentations · 2
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2024-10-14partnershipzanzalintinib · Clinical development collaboration with Merck to evaluate zanzalintinib with KEYTRUDA in HNSCC and with WELIREG in RCCSEC 8-K
Approved drugs (2)
- CABOMETYXCABOZANTINIB S-MALATE2016 · Prescription
- COMETRIQCABOZANTINIB S-MALATE2012 · Prescription
Capital structure — dilution & financing
Shares out: 251,355,083 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $51 (-7% upside) · 15 analysts
- 2026-07-14BarclaysEqual-Weight
- 2026-07-13Wells FargoEqual-Weight
- 2026-07-07RBC CapitalSector Perform
- 2026-07-07Truist SecuritiesHold
- 2026-07-02UBSNeutral
- 2026-07-02HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- TNGXTango Therapeutics, Inc.$4.0B · D5
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-23Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 - BioSpace
- 2026-07-23Exelixis to release Q2 2026 financial results on August 5 - scanx.trade
- 2026-07-22Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 - Business Wire
- 2026-07-22Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 - lincolnjournal.com
- 2026-07-21Lobbying Update: $560,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
- 2026-07-20Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
- 2026-07-18(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
- 2026-07-16Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.